Antitumor efficacy and toxicity of methyltrienolone (NSC-92858) in advanced breast cancer
Halden, A.; Walter, R.M.; Gordan, G.S.
Cancer ChemoTherapy Reports 54(6): 453-455
1970
ISSN/ISBN: 0069-0112 PMID: 4946014 Document Number: 18974
Document emailed within 1 workday
Related Documents
Zheng, J.; Wang, H.; Yao, J.; Zou, X. 2014: More antitumor efficacy of the PI3K inhibitor GDC-0941 in breast cancer with PIK3CA mutation or HER2 amplification status in vitro Die Pharmazie 69(1): 38-42Chiba, A.; Shimizu, S.; Yoshida, A.; Inaba, M.; Matsuura, H.; Ino, H.; Suganuma, N.; Inari, H.; Yamanaka, T.; Kuroda, K.; Mukaibashi, T.; Matsuo, A.; Kojima, I. 2012: Efficacy and toxicity of lapatinib plus capecitabine therapy in HER2-positive metastatic breast cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 39(11): 1675-1679
Saha, K.; Kapila, H.; Madan, R.; Shinghal, R.N. 1986: Immunologic tools to decipher efficacy of BCG immunotherapy in advanced breast cancer: a one year follow up study Asian Pacific Journal of Allergy and Immunology 4(2): 139-148
Kubota, O.; Onuki, Y.; Uchiyama, T.; Oishi, K.; Takeda, M. 2012: Efficacy of high-dose toremifene as a second-line hormone therapy in patients with advanced or metastatic breast cancer resistant to aromatase inhibitor Gan to Kagaku Ryoho. Cancer and ChemoTherapy 39(5): 753-757
Bozeman, E.N.; Srivatsan, S.; Mohammadi, H.; Daniels, D.; Shashidharamurthy, R.; Selvaraj, P. 2012: Ukrain, a plant derived semi-synthetic compound, exerts antitumor effects against murine and human breast cancer and induce protective antitumor immunity in mice Experimental Oncology 34(4): 340-347
Ohtake, T.; Yasuda, M.; Watanabe, K.; Ito, T.; Ito, J.; Miyamoto, K.; Yoshida, S.; Abe, N.; Ishigame, T.; Ishii, M.; Kimijima, I.; Takenoshita, S. 2009: Efficacy and safety of high-dose toremifene for hormone-responsive advanced or metastatic breast cancer patients with failed prior treatment by aromatase inhibitors Gan to Kagaku Ryoho. Cancer and ChemoTherapy 36(9): 1459-1463
Ohtani, H.; Arimoto, Y.; Nishio, K.; Kanamiya, Y.; Oba, H.; Adachi, K.; Shintani, M.; Nakamura, R.; Yui, S. 2008: Efficacy and toxicity of fluorouracil, leucovorin plus oxaliplatin (FOLFOX4 and modified FOLFOX6) followed by fluorouracil, leucovorin plus irinotecan(FOLFIRI)for advanced or metastatic colorectal cancer--case studies Gan to Kagaku Ryoho. Cancer and ChemoTherapy 35(10): 1769-1774
Stamatovic, L.; Susnjar, S.; Gavrilovic, D.; Minic, I.; Ursulovic, T.; Dzodic, R. 2018: The influence of breast cancer subtypes on the response to anthracycline neoadjuvant chemotherapy in locally advanced breast cancer patients Journal of Buon: Official Journal of the Balkan Union of Oncology 23(5): 1273-1280
Chagpar, A.B. 2007: Insights into the management of locally advanced, inflammatory, and metastatic breast cancer: highlights from the 2007 Louisville Breast Cancer Update Journal of the Kentucky Medical Association 105(11): 559-560
Albeshan, S.M.; Hossain, S.Z.; Mackey, M.G.; Brennan, P.C. 2020: Can Breast Self-examination and Clinical Breast Examination Along with Increasing Breast Awareness Facilitate Earlier Detection of Breast Cancer in Populations with Advanced Stages at Diagnosis? Clinical Breast Cancer 20(3): 194-200
Saksornchai, K.; Rojpornpradit, P.; Shotelersak, K.; Lertbutsayanukul, C.; Chakkabat, C.; Raiyawa, T. 2012: Skin toxicity and cosmesis after hypofractionated whole breast irradiation for early breast cancer Journal of the Medical Association of Thailand 95(2): 229-240
Taguchi, T.; Koyama, H.; Yayoi, K.; Wada, T.; Takatsuka, Y.; Sonoo, H.; Morimoto, K.; Tominaga, T.; Abe, R.; Enomoto, K. 1995: Long-term clinical study on TAP-144-SR, an LH-RH agonist depot formulation, in premenopausal patients with advanced or recurrent breast cancer. TAP-144-SR Breast Cancer Study Group Gan to Kagaku Ryoho. Cancer and ChemoTherapy 22(4): 495-508
Cao, S.; Troutt, A.B.; Rustum, Y.M. 1998: Interleukin 15 protects against toxicity and potentiates antitumor activity of 5-fluorouracil alone and in combination with leucovorin in rats bearing colorectal cancer Cancer Research 58(8): 1695-1699
1974: Assessment of response to treatment in advanced breast cancer. British Breast Group Lancet 2(7871): 38-39
Aft, R. 2011: Bisphosphonates in breast cancer: antitumor effects Clinical Advances in Hematology and Oncology: H&o 9(4): 292-299
Suda, K.; Kano, Y.; Inada, T.; Ogata, Y. 1993: Etoposide, doxorubicin, cisplatin and 5-FU (EAP-F) therapy of advanced gastric cancer--its antitumor effect and evaluation of quality of life Gan to Kagaku Ryoho. Cancer and ChemoTherapy 20(12): 1791-1795
Jakubowicz, J.; Blecharz, P.; Skotnicki, P.; Reinfuss, M.; Walasek, T.; Luczynska, E. 2014: Toxicity of concurrent chemoradiotherapy for locally advanced cervical cancer European Journal of Gynaecological Oncology 35(4): 393-399
Kharkevich, D.D. 1988: Effect of dopamine on the antitumor immunity of patients with breast cancer Farmakologiia i Toksikologiia 51(3): 86-89
Tominaga, T.; Nomura, Y.; Adachi, I.; Aoyama, H.; Nagao, K.; Mitsuyama, S.; Nakamura, Y.; Ogita, M.; Sano, M.; Takashima, S. 1994: Late phase II study of KW-2307 in advanced or recurrent breast cancer. KW-2307 Cooperative Study Group (Breast Cancer Section) Gan to Kagaku Ryoho. Cancer and ChemoTherapy 21(6): 809-816
Sica, G.; Lama, G.; Iacopino, F.; Angelucći, C.; Della Cuna, G.R.; Marchetti, P. 1991: Antitumor effect of lonidamine alone or combined with tamoxifen or medroxyprogesterone acetate in breast cancer cells Anticancer Research 11(6): 2099-2102